title: Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
abstract: OBJECTIVE
  Carbonic anhydrase (CA) isozymes IX and XII have been suggested to play a role in oncogenic processes. The aim of the present study was to investigate CA IX and XII expression in patients with ovarian tumours.
  
  
  RESULTS
  A series of ovarian tumours was immunostained for CA IX and XII and the results were correlated with histopathological and clinical parameters. Most cases of borderline mucinous cystadenomas, mucinous cystadenocarcinomas and serous cystadenocarcinomas were moderately or strongly positive for CA IX. In malignant tumours, the staining was most prominent in hypoxic regions. Expression of CA XII was detected in all tumour categories, although the mean staining intensity was weaker than for CA IX in all groups except for clear cell carcinomas.
  
  
  CONCLUSIONS
  The wide expression of CA IX and XII in ovarian tumours suggests that these isozymes could represent potential targets in ovarian cancer therapy. The expression pattern of CA IX suggests that it could also serve as a useful histopathological marker protein for hypoxia in malignant ovarian tumours.
authors.affiliation: Department of Obstetrics and Gynaecology, Tampere University Hospital, University of Tampere, Tampere, Finland.
authors.forename: P
authors.initials: P
authors.lastname: Hynninen
authors.forename: L
authors.initials: L
authors.lastname: Vaskivuo
authors.forename: J
authors.initials: J
authors.lastname: Saarnio
authors.forename: H
authors.initials: H
authors.lastname: Haapasalo
authors.forename: J
authors.initials: J
authors.lastname: Kivelä
authors.forename: S
authors.initials: S
authors.lastname: Pastoreková
authors.forename: J
authors.initials: J
authors.lastname: Pastorek
authors.forename: A
authors.initials: A
authors.lastname: Waheed
authors.forename: W S
authors.initials: WS
authors.lastname: Sly
authors.forename: U
authors.initials: U
authors.lastname: Puistola
authors.forename: S
authors.initials: S
authors.lastname: Parkkila
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000378:metabolism*; D002462:Cell Membrane / Q000201:enzymology* / Q000473:pathology; D018282:Cystadenocarcinoma, Mucinous / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D018291:Cystadenoma, Mucinous / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D007124:Immunoenzyme Techniques; D007527:Isoenzymes; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
chemical_list: D000951:Antigens, Neoplasm; D007527:Isoenzymes; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases; C477378:carbonic anhydrase XII